Sarcoidosis

Sarcoidosis is a systemic granulomatous disease characterized by the formation of granulomas in various organs and systems of the body, primarily in the lungs, lymph nodes, and skin. The etymology of the term "sarcoidosis" comes from the Greek word "sarkoid", which translates as "fleshy", reflecting the characteristic manifestations of the disease. These granulomas are accumulations of immune cells, and their formation leads to dysfunction of the affected organs. Sarcoidosis has a variable clinical course: in some patients, the disease may be asymptomatic and resolve on its own, while in others it may be more aggressive and cause significant deterioration in health. Despite advances in the study of sarcoidosis, its etiology remains unclear, which complicates diagnosis and treatment.

History of the disease and interesting historical facts

Sarcoidosis was first described in 1877 by Swedish dermatologist Hans-Johan Gap, who mentioned the cutaneous form of the disease. In 1946, Californian physician Edgar Vernall conducted the first studies on the systemic manifestations of sarcoidosis, which opened a new stage in understanding the disease. Interestingly, sarcoidosis was called the "disease of blacks" due to the fact that it was more often observed in African Americans, however, this name is not entirely accurate, since the disease also occurs in people of other races. Later studies showed a possible connection between sarcoidosis and certain exogenous factors, such as exposure to chemicals and infectious agents, which opens up new perspectives for further research.

Epidemiology

Sarcoidosis has different epidemiological characteristics depending on the geographic region. The disease is mainly registered in Northern Europe and North America. According to epidemiological studies, the annual incidence of sarcoidosis ranges from 10 to 40 cases per 100,000 population. In particular, among African Americans, the incidence is higher and is approximately 50-100 cases per 100,000 people. Taking into account the data from different studies, the following characteristics can be distinguished:

• Age of onset: most often occurs between the ages of 20 and 40 years.
• Gender: Women are slightly more likely to develop the disease than men.
• Racial characteristics: higher incidence in people of African descent.

Genetic predisposition to this disease

Modern genetic studies have demonstrated that genetic predisposition plays a significant role in the development of sarcoidosis. In particular, a link has been identified with a number of genes, such as HLA-DRB1, which can modify the immune response to the introduction of infectious agents or other antigens. The study of polymorphisms of these genes suggests that the presence of certain alleles may increase the risk of developing the disease.

According to research, molecules such as TNF-α also have a genetic association with sarcoidosis, as they are involved in the inflammatory process and the formation of granulomas. In some cases, there is a familial predisposition to the disease, which also confirms the importance of genetic factors in its development.

Risk factors for the development of this disease

There are a number of factors that can contribute to the development of sarcoidosis. The main ones include:

• Environmental factors: exposure to dust, chemicals and allergens.
• Infectious factors: Some studies suggest a link with infections such as mycobacteria and viruses.
• Occupational factors: working in certain environments such as mining, medicine and manufacturing where there is a risk of exposure to toxic substances.
• Immune disorders: People with pre-existing autoimmune diseases may be at increased risk of sarcoidosis.

The importance of understanding these factors is that they can aid in early diagnosis and prevention of the disease.

Diagnosis of this disease

Diagnosis of sarcoidosis usually involves a comprehensive approach and is based on clinical presentation, laboratory test results, and radiological examinations. The main symptoms include:

• Fatigue and general weakness.
• Cough and shortness of breath are most often observed when the lungs are affected.
• Skin rash and lymphadenopathy.
• Signs of uveitis or other ophthalmologic manifestations.

Laboratory tests may include blood calcium levels, as well as pulmonary function tests and bronchography. Radiological tests, such as chest x-rays and CT scans, may reveal specific changes, including enlarged lymph nodes and granulomas in the lungs.

Differential diagnosis should be made with other diseases such as tuberculosis, granulomatous vasculitis, and interstitial lung diseases.

Treatment

Treatment of sarcoidosis depends on the severity of the disease and the extent of organ damage. In most cases, the disease resolves on its own, but if symptoms are severe and the quality of life is negatively affected, the following approaches may be taken:

• General treatment: Patients with mild sarcoidosis may be advised to remain vigilant without active intervention.
• Pharmacological treatment: Corticosteroids such as prednisolone are used to reduce the inflammatory response.
• Surgical treatment: may be required in severe cases, when granulomatous lesions are removed.
• Other treatments: Immunosuppressants (eg, methotrexate) are used if corticosteroids are ineffective or if there are side effects from their use.

List of medications used to treat this disease

The main drugs used to treat sarcoidosis include:

• Prednisolone.
• Methotrexate.
• Azaathioprinin.
• Leflunomide.
• Tafasitinib (in severe cases).

Disease monitoring

Monitoring the health of patients with sarcoidosis includes regular follow-up examinations, such as chest X-rays, respiratory function assessment, and blood tests. It is important to record the dynamics of the disease, identify possible complications, such as pneumosclerosis or dyspnea.

The prognosis for sarcoidosis varies. In most cases, the disease can resolve on its own without negative consequences. However, severe forms can lead to persistent changes and deterioration of organ function. Complications may include respiratory disorders and systemic symptoms for some time.

Age-related features of the disease

Sarcoidosis can manifest itself in different age groups, but the highest incidence is observed in young and middle-aged people, especially between the ages of 20 and 40. In children, sarcoidosis can manifest itself in mild forms, less often with severe complications. Younger patients exhibit a different clinical course, with a higher incidence of chronic manifestations and comorbidities which may complicate treatment and diagnosis.

Questions and Answers

• What is sarcoidosis? Sarcoidosis is a systemic granulomatous disease characterized by the formation of granulomas in various organs.
• What are the symptoms of sarcoidosis? Symptoms may include fatigue, shortness of breath, cough, skin rashes, and uveitis.
• How is sarcoidosis diagnosed? Diagnosis includes clinical examination, laboratory and radiological studies, and differential diagnosis.
• What treatment is recommended for sarcoidosis? Treatment may include observation, corticosteroids, and other immunosuppressive medications.
• What is the prognosis for sarcoidosis? The prognosis varies from complete spontaneous resolution to chronic forms with possible complications.